Successful treatment of bullous pemphigoid with omalizumab

Archives of Dermatology

Volumn 148, Issue 11, 2012, Pages 1241-1243

  London, Vanessa A ^a   Kim, Gene H ^a   Fairley, Janet A ^b   Woodley, David T ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISONE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; EOSINOPHILIA; EROSION; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; EOSINOPHILS; FEMALE; HUMANS; IMMUNOGLOBULIN E; PEMPHIGOID, BULLOUS; TREATMENT OUTCOME;

EID: 84869836492     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.1604     Document Type: Article

References (12)

1. Patton T, Korman NJ. Bullous pemphigoid treatment review. Expert Opin Pharmacother. 2006;7(17):2403-2411. (Pubitemid 44842921)
2. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704-705.
3. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. 1997;100(5):1256-1263. (Pubitemid 27386312)
4. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol. 2007;127(11):2605-2611. (Pubitemid 47585071)
5. Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol. 2007;127(5):1167-1174. (Pubitemid 46625148)
6. Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120(5):784-788. (Pubitemid 36529079)
7. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128(12):1626-1630. (Pubitemid 23001181)
8. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728-1736.
9. Heimbach L, Li N, Diaz A, Liu Z. Experimental animal models of bullous pemphigoid. G Ital Dermatol Venereol. 2009;144(4):423-431.
10. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772-1779. (Pubitemid 44631360)
11. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552. (Pubitemid 47236279)
12. Joly P, D'Incan M, Musette P. Rituximab for pemphigus vulgaris. N Engl J Med. 2007;356(5):521-522.